Comparative Effectiveness of Combining MTX with Biologic Drug Therapy Versus Either MTX or Biologics Alone for Early Rheumatoid Arthritis in Adults: a Systematic Review and Network Meta-analysis. (Q67396259)

From Wikidata

Jump to navigation Jump to search

scientific article published on 06 August 2019

Language	Label	Description	Also known as
English	Comparative Effectiveness of Combining MTX with Biologic Drug Therapy Versus Either MTX or Biologics Alone for Early Rheumatoid Arthritis in Adults: a Systematic Review and Network Meta-analysis.	scientific article published on 06 August 2019

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31388915%20AND%20SRC:MED&resulttype=core&format=json

29 April 2020

Comparative Effectiveness of Combining MTX with Biologic Drug Therapy Versus Either MTX or Biologics Alone for Early Rheumatoid Arthritis in Adults: a Systematic Review and Network Meta-analysis (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31388915%20AND%20SRC:MED&resulttype=core&format=json

29 April 2020

Drug Therapy for Early Rheumatoid Arthritis: A Systematic Review Update

0 references

Patient-Centered Outcomes Research Institute

0 references

rheumatoid arthritis

1 reference

based on heuristic

inferred from title

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31388915%20AND%20SRC:MED&resulttype=core&format=json

29 April 2020

Gerald Gartlehner

3

object named as

Gerald Gartlehner

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31388915%20AND%20SRC:MED&resulttype=core&format=json

29 April 2020

Rachel Palmieri Weber

7

object named as

Rachel Palmieri Weber

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31388915%20AND%20SRC:MED&resulttype=core&format=json

29 April 2020

author name string

Katrina E Donahue

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31388915%20AND%20SRC:MED&resulttype=core&format=json

29 April 2020

Elizabeth R Schulman

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31388915%20AND%20SRC:MED&resulttype=core&format=json

29 April 2020

Beth L Jonas

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31388915%20AND%20SRC:MED&resulttype=core&format=json

29 April 2020

Emmanuel Coker-Schwimmer

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31388915%20AND%20SRC:MED&resulttype=core&format=json

29 April 2020

Sheila V Patel

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31388915%20AND%20SRC:MED&resulttype=core&format=json

29 April 2020

Meera Viswanathan

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31388915%20AND%20SRC:MED&resulttype=core&format=json

29 April 2020

language of work or name

0 references

publication date

6 August 2019

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31388915%20AND%20SRC:MED&resulttype=core&format=json

29 April 2020

Journal of General Internal Medicine

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31388915%20AND%20SRC:MED&resulttype=core&format=json

29 April 2020

34

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31388915%20AND%20SRC:MED&resulttype=core&format=json

29 April 2020

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31388915%20AND%20SRC:MED&resulttype=core&format=json

29 April 2020

2232-2245

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31388915%20AND%20SRC:MED&resulttype=core&format=json

29 April 2020

A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/31388915

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Eligibility of patients in routine care for major clinical trials of anti-tumor necrosis factor alpha agents in rheumatoid arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/31388915

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/31388915

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: Results from a twe

1 reference

https://pubmed.ncbi.nlm.nih.gov/31388915

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/31388915

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had

1 reference

https://pubmed.ncbi.nlm.nih.gov/31388915

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Infliximab treatment maintains employability in patients with early rheumatoid arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/31388915

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomized phase 2 trial of anti-tumor necrosis factor therapy for cachexia in patients with early rheumatoid arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/31388915

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment of early rheumatoid arthritis: a randomized magnetic resonance imaging study comparing the effects of methotrexate alone, methotrexate in combination with infliximab, and methotrexate in combination with intravenous pulse methylprednisolon

1 reference

https://pubmed.ncbi.nlm.nih.gov/31388915

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Adalimumab plus methotrexate improved SF-36 scores and reduced the effect of rheumatoid arthritis (RA) on work activity for patients with early RA.

1 reference

https://pubmed.ncbi.nlm.nih.gov/31388915

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and tumour necrosis factor blockade

1 reference

https://pubmed.ncbi.nlm.nih.gov/31388915

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/31388915

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of the early use of the anti-tumor necrosis factor adalimumab on the prevention of job loss in patients with early rheumatoid arthritis.

1 reference

https://pubmed.ncbi.nlm.nih.gov/31388915

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors

1 reference

https://pubmed.ncbi.nlm.nih.gov/31388915

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Patient-reported outcomes improve with etanercept plus methotrexate in active early rheumatoid arthritis and the improvement is strongly associated with remission: the COMET trial.

1 reference

https://pubmed.ncbi.nlm.nih.gov/31388915

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/31388915

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The effect of etanercept on work productivity in patients with early active rheumatoid arthritis: results from the COMET study

1 reference

https://pubmed.ncbi.nlm.nih.gov/31388915

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Two-year clinical and radiographic results with combination etanercept-methotrexate therapy versus monotherapy in early rheumatoid arthritis: A two-year, double-blind, randomized study

1 reference

https://pubmed.ncbi.nlm.nih.gov/31388915

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Disease Activity, Physical Function, and Radiographic Progression After Longterm Therapy with Adalimumab Plus Methotrexate: 5-Year Results of PREMIER

1 reference

https://pubmed.ncbi.nlm.nih.gov/31388915

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/31388915

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of rituximab on physical function and quality of life in patients with rheumatoid arthritis previously untreated with methotrexate

1 reference

https://pubmed.ncbi.nlm.nih.gov/31388915

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Does achieving clinical response prevent work stoppage or work absence among employed patients with early rheumatoid arthritis?

1 reference

https://pubmed.ncbi.nlm.nih.gov/31388915

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Sustained disease remission and inhibition of radiographic progression in methotrexate-naive patients with rheumatoid arthritis and poor prognostic factors treated with abatacept: 2-year outcomes.

1 reference

https://pubmed.ncbi.nlm.nih.gov/31388915

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Abatacept plus methotrexate provides incremental clinical benefits versus methotrexate alone in methotrexate-naive patients with early rheumatoid arthritis who achieve radiographic nonprogression

1 reference

https://pubmed.ncbi.nlm.nih.gov/31388915

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Sustained inhibition of progressive joint damage with rituximab plus methotrexate in early active rheumatoid arthritis: 2-year results from the randomised controlled trial IMAGE.

1 reference

https://pubmed.ncbi.nlm.nih.gov/31388915

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Health-related quality of life outcomes of adalimumab for patients with early rheumatoid arthritis: results from a randomized multicenter study

1 reference

https://pubmed.ncbi.nlm.nih.gov/31388915

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Diagnosis and management of rheumatoid arthritis.

1 reference

https://pubmed.ncbi.nlm.nih.gov/31388915

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical, functional and radiographic consequences of achieving stable low disease activity and remission with adalimumab plus methotrexate or methotrexate alone in early rheumatoid arthritis: 26-week results from the randomised, controlled OPTIMA s

1 reference

https://pubmed.ncbi.nlm.nih.gov/31388915

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Induction therapy with adalimumab plus methotrexate for 24 weeks followed by methotrexate monotherapy up to week 48 versus methotrexate therapy alone for DMARD-naive patients with early rheumatoid arthritis: HIT HARD, an investigator-initiated study

1 reference

https://pubmed.ncbi.nlm.nih.gov/31388915

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Infliximab for 6 months added on combination therapy in early rheumatoid arthritis: 2-year results from an investigator-initiated, randomised, double-blind, placebo-controlled study (the NEO-RACo Study).

1 reference

https://pubmed.ncbi.nlm.nih.gov/31388915

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Association of joint space narrowing with impairment of physical function and work ability in patients with early rheumatoid arthritis: protection beyond disease control by adalimumab plus methotrexate

1 reference

https://pubmed.ncbi.nlm.nih.gov/31388915

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Adalimumab, a human anti-TNF monoclonal antibody, outcome study for the prevention of joint damage in Japanese patients with early rheumatoid arthritis: the HOPEFUL 1 study

1 reference

https://pubmed.ncbi.nlm.nih.gov/31388915

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Adalimumab added to a treat-to-target strategy with methotrexate and intra-articular triamcinolone in early rheumatoid arthritis increased remission rates, function and quality of life. The OPERA Study: an investigator-initiated, randomised, double-

1 reference

https://pubmed.ncbi.nlm.nih.gov/31388915

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

M-ficolin levels reflect disease activity and predict remission in early rheumatoid arthritis.

1 reference

https://pubmed.ncbi.nlm.nih.gov/31388915

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/31388915

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Longterm effect of delaying combination therapy with tumor necrosis factor inhibitor in patients with aggressive early rheumatoid arthritis: 10-year efficacy and safety of adalimumab from the randomized controlled PREMIER trial with open-label exten

1 reference

https://pubmed.ncbi.nlm.nih.gov/31388915

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A treat-to-target strategy with methotrexate and intra-articular triamcinolone with or without adalimumab effectively reduces MRI synovitis, osteitis and tenosynovitis and halts structural damage progression in early rheumatoid arthritis: results fr

1 reference

https://pubmed.ncbi.nlm.nih.gov/31388915

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Recovery of clinical but not radiographic outcomes by the delayed addition of adalimumab to methotrexate-treated Japanese patients with early rheumatoid arthritis: 52-week results of the HOPEFUL-1 trial.

1 reference

https://pubmed.ncbi.nlm.nih.gov/31388915

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Early start and stop of biologics: has the time come?

1 reference

https://pubmed.ncbi.nlm.nih.gov/31388915

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

When to adjust therapy in patients with rheumatoid arthritis after initiation of etanercept plus methotrexate or methotrexate alone: findings from a randomized study (COMET)

1 reference

https://pubmed.ncbi.nlm.nih.gov/31388915

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Evaluating drug-free remission with abatacept in early rheumatoid arthritis: results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24 months, with a 12-month, double-blind treatment period

1 reference

https://pubmed.ncbi.nlm.nih.gov/31388915

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Grading the strength of a body of evidence when assessing health care interventions: an EPC update.

1 reference

https://pubmed.ncbi.nlm.nih.gov/31388915

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Existing joint erosions increase the risk of joint space narrowing independently of clinical synovitis in patients with early rheumatoid arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/31388915

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Consistency and inconsistency in network meta-analysis: model estimation using multivariate meta-regression

1 reference

https://pubmed.ncbi.nlm.nih.gov/31388915

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Attainment and characteristics of clinical remission according to the new ACR-EULAR criteria in abatacept-treated patients with early rheumatoid arthritis: new analyses from the Abatacept study to Gauge Remission and joint damage progression in meth

1 reference

https://pubmed.ncbi.nlm.nih.gov/31388915

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The first double-blind, randomised, parallel-group certolizumab pegol study in methotrexate-naive early rheumatoid arthritis patients with poor prognostic factors, C-OPERA, shows inhibition of radiographic progression

1 reference

https://pubmed.ncbi.nlm.nih.gov/31388915

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical and radiographic outcome of a treat-to-target strategy using methotrexate and intra-articular glucocorticoids with or without adalimumab induction: a 2-year investigator-initiated, double-blinded, randomised, controlled trial (OPERA).

1 reference

https://pubmed.ncbi.nlm.nih.gov/31388915

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Tocilizumab in early progressive rheumatoid arthritis: FUNCTION, a randomised controlled trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/31388915

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/31388915

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A randomised trial evaluating anakinra in early active rheumatoid arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/31388915

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical trials of new drugs for the treatment of rheumatoid arthritis: focus on early disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/31388915

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of adalimumab on the work-related outcomes scores in patients with early rheumatoid arthritis receiving methotrexate

1 reference

https://pubmed.ncbi.nlm.nih.gov/31388915

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Certolizumab pegol in combination with dose-optimised methotrexate in DMARD-naïve patients with early, active rheumatoid arthritis with poor prognostic factors: 1-year results from C-EARLY, a randomised, double-blind, placebo-controlled phase III st

1 reference

https://pubmed.ncbi.nlm.nih.gov/31388915

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Tumour necrosis factor inhibition versus rituximab for patients with rheumatoid arthritis who require biological treatment (ORBIT): an open-label, randomised controlled, non-inferiority, trial.

1 reference

https://pubmed.ncbi.nlm.nih.gov/31388915

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Early rheumatoid arthritis treated with tocilizumab, methotrexate, or their combination (U-Act-Early): a multicentre, randomised, double-blind, double-dummy, strategy trial.

1 reference

https://pubmed.ncbi.nlm.nih.gov/31388915

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions

1 reference

https://pubmed.ncbi.nlm.nih.gov/31388915

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Hand bone loss in early rheumatoid arthritis during a methotrexate-based treat-to-target strategy with or without adalimumab-a substudy of the optimized treatment algorithm in early RA (OPERA) trial.

1 reference

https://pubmed.ncbi.nlm.nih.gov/31388915

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update

1 reference

https://pubmed.ncbi.nlm.nih.gov/31388915

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Network meta-analysis: application and practice using Stata

1 reference

https://pubmed.ncbi.nlm.nih.gov/31388915

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S11606-019-05230-0

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31388915%20AND%20SRC:MED&resulttype=core&format=json

29 April 2020

PMC publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31388915%20AND%20SRC:MED&resulttype=core&format=json

29 April 2020

Semantic Scholar paper ID

3568778f84c82dc7dfdd1f9f841da99236f0dc8b

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q67396259&oldid=2241380256"